ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.98
-0.45%
US Tech 100
16,963.33
-0.57%
Dow Jones
38,086.27
-0.97%
Brent Oil
88.085
0.99%
Bitcoin
64,642.18
0.56%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rigel Pharmaceuticals Inc (RIGL) Quote

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
1.085
-0.04
( -3.56% )
Updated: 15:43:13
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.085
Bid
1.08
Ask
1.09
Volume
488,643
1.06 Day's Range 1.14
0.712 52 Week Range 1.96
Market Cap
189.408M
Previous Close
1.125
Open
1.1199
Last Trade
8
@
1.085
Last Trade Time
15:43:43
Financial Volume
$ 533,457
VWAP
1.0917
Average Volume (3m)
1,495,161
Shares Outstanding
175,377,812
Dividend Yield
-
PE Ratio
-7.55
Earnings Per Share (EPS)
-0.14
Revenue
116.88M
Net Profit
-25.09M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Ri... Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rigel.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $1.13. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 0.712 to $ 1.96.

Rigel Pharmaceuticals currently has 175,377,812 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $189.41 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.55.

RIGL Latest News

More News

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., April 10, 2024 SOUTH SAN FRANCISCO, Calif., April 10, 2024 /PRNewswire/ -- Rigel...

April 10 2024
PR Newswire (US)

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma PR Newswire SOUTH SAN FRANCISCO, Calif., April 4, 2024...

April 04 2024
PR Newswire (US)

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif., March 12, 2024 SOUTH SAN FRANCISCO, Calif., March 12, 2024...

March 12 2024
PR Newswire (US)

Form 8-K - Current report

March 05 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 05 2024
Edgar (US Regulatory)

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., March 5, 2024 Fourth quarter 2023 Total Revenue of $35.8...

March 05 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.035-3.1251.121.171.0124714141.11651993CS
4-0.385-26.19047619051.471.5051.0119790161.2147628CS
12-0.105-8.823529411761.191.731.0114951611.31328901CS
260.303638.85334015870.78141.730.71212216911.24101236CS
52-0.055-4.824561403511.141.960.71214261911.27898256CS
156-2.595-70.51630434783.684.620.6424179381.73944103CS
260-1.205-52.62008733622.295.50.6425559762.30523822CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BRFHBarfresh Food Group Inc
$ 1.805
(75.24%)
43.01M
SGBXSafe and Green Holdings Corporation
$ 0.2467
(71.20%)
132.07M
PCSAProcessa Pharmaceuticals Inc
$ 2.4393
(50.57%)
74.6M
BACKIMAC Holdings Inc
$ 5.1216
(46.96%)
7.78M
ACONAclarion Inc
$ 0.4035
(40.10%)
111.86M
EJHE Home Household Service Holdings Ltd
$ 0.7699
(-73.54%)
11.72M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.262
(-38.40%)
15.46M
ATNIATN International Inc
$ 19.445
(-32.29%)
340.1k
BNAIBrand Engagement Network Inc
$ 2.61
(-30.03%)
209.82k
RWODURedwoods Acquisition Corporation
$ 5.50
(-29.49%)
310
SQQQProShares UltraPro Short QQQ
$ 11.965
(1.31%)
147.64M
SGBXSafe and Green Holdings Corporation
$ 0.25
(73.49%)
132.24M
ACONAclarion Inc
$ 0.3933
(36.56%)
111.92M
TSLATesla Inc
$ 170.06
(4.89%)
108.81M
METAMeta Platforms Inc
$ 441.8545
(-10.47%)
76.77M

RIGL Discussion

View Posts
dcaf7 dcaf7 1 day ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 3 days ago
RIGL under $2
👍️0
Monksdream Monksdream 4 weeks ago
RIGL under $2
👍️0
dcaf7 dcaf7 4 weeks ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 1 month ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 2 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 9 months ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 9 months ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 10 months ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 10 months ago
Better be good.
👍️0
bme bme 10 months ago
Ugly.
👍️0
The Night Stalker The Night Stalker 10 months ago
nice
👍️0
The Night Stalker The Night Stalker 10 months ago
nice
👍️0
The Night Stalker The Night Stalker 10 months ago
base
👍️0
bme bme 10 months ago
What a shoot! Amazing.
👍️0
bme bme 10 months ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 10 months ago
nice fins
👍️0
The Night Stalker The Night Stalker 10 months ago
gem
👍️0
The Night Stalker The Night Stalker 10 months ago
gem
👍️0
The Night Stalker The Night Stalker 11 months ago
easy
👍️0
bme bme 11 months ago
Nice spike AH today.
👍️0
bme bme 11 months ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 11 months ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 11 months ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 11 months ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
bme bme 11 months ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 11 months ago
quite the dip
👍️0
The Night Stalker The Night Stalker 11 months ago
ready
👍️0
The Night Stalker The Night Stalker 11 months ago
ready
👍️0
The Night Stalker The Night Stalker 11 months ago
red to green
👍️0
The Night Stalker The Night Stalker 11 months ago
red to green
👍️0
bme bme 11 months ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 11 months ago
beauty
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
bme bme 1 year ago
Expect Q4 filing this week?
👍️0
bme bme 1 year ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 1 year ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 1 year ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 1 year ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 1 year ago
RIGL news out
👍️0
bme bme 1 year ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 1 year ago
Just like ABQQ. Right?
👍️0
subslover subslover 1 year ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 1 year ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 1 year ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 1 year ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 1 year ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 1 year ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 1 year ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

NASDAQ
RIGL
Rigel Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved